10/21/2026
Psyence BioMed finalizes $2.6M investment in PsyLabs
Psyence BioMed invests in PsyLabs following milestone achievements.
Topic archive
psychedelic research
22 stories
10/16/2026
Lilly explores ibogaine research opportunities
Pharmaceutical giant Lilly shows interest in advancing ibogaine studies.
10/9/2026
FDA seeks input on ibogaine trials amid safety concerns
FDA's request for ibogaine trial proposals highlights cardiac risks and regulatory challenges.
10/8/2026
Texas ibogaine trials face funding gap as federal support looms
Federal funds may replace private investment in Texas ibogaine research
10/6/2026
US funds ibogaine trials for opioid addiction
Trump administration allocates $50M for ibogaine research
10/5/2026
US launches government-funded ibogaine trials
First federally backed ibogaine trials mark a shift in psychedelic research.
10/5/2026
US initiates government-funded ibogaine trials
First federally backed ibogaine trials mark a significant step in psychedelic research.
9/23/2026
Ibogaine under scrutiny after Presley Gerber's death
No link established between ibogaine and Gerber's death, but heart risks persist.
9/22/2026
NIH funds ibogaine study for opioid addiction with heart safety focus
Brigham and Women's Hospital receives $2.3 million to assess ibogaine's safety for opioid use disorder.
9/21/2026
Ibogaine gains attention for addiction treatment
Psychedelic compound ibogaine draws interest amid regulatory shifts.
9/21/2026
Atypical psychedelics: clinical insights
Exploring lesser-known psychedelics and their potential therapeutic roles.
8/21/2026
Johnson & Johnson invests in Delix Therapeutics
Investment in neuroplastogen company highlights growing interest in non-hallucinogenic psychedelics.
8/21/2026
Ibogaine research gains momentum for PTSD treatment
Trump administration accelerates psychedelic research for veterans' mental health.
8/19/2026
Psyence Biomedical welcomes U.S. support for ibogaine
U.S. backing could accelerate ibogaine research for mental health.
8/19/2026
Psyence Biomedical stock rises 27% on ibogaine research
Market optimism grows as Psyence Biomedical advances ibogaine studies.
8/19/2026
Trump emphasizes ibogaine development, Psyence BioMed reacts
Former President Trump supports ibogaine research, sparking industry response.
8/10/2026
Barrow Neurological Institute secures $5M for ibogaine brain injury trial
Arizona funds first U.S. ibogaine trial for traumatic brain injuries, starting 2027.
8/10/2026
Ibogaine trials for opioid use disorder get ARPA-H boost
ARPA-H seeks to accelerate ibogaine trials for opioid treatment
7/29/2026
Ibogaine research faces representation challenges
Psychedelic trials often exclude marginalized groups, raising questions about equity and efficacy.
7/29/2026
Texas initiates ibogaine research with federal support
State-led ibogaine study in Texas gains federal backing, marking a significant research development.
7/24/2026
Trump administration fast-tracks ibogaine research
Psychoactive drug ibogaine gains attention for addiction treatment potential.
7/17/2026
Eli Lilly acquires 5-MeO-DMT developer for $3.8B
Pharmaceutical giant expands into psychedelic research with major acquisition.